A new therapeutic strategy using an artificial LRP1-binding peptide with identical residue sequences as ligands recognizing the specific binding domains of the LRP1 α-subunit to suppress the development of MetS was developed (59). This evidence concerns the gene LRP1 and metabolic syndrome.